Search for: "Doe v. Solvay Pharmaceuticals, Inc."
Results 1 - 20
of 23
Sorted by Relevance
|
Sort by Date
28 May 2014, 10:31 am
In April 1999, Solvay Pharmaceuticals, LLC (“Solvay”) filed a New Drug Application (“NDA”) with the Food and Drug Administration (“FDA”) seeking approval to commercially market a testosterone replacement gel (“AndroGel”). [read post]
25 Jun 2013, 9:51 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
24 Jun 2013, 10:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
24 Jun 2013, 6:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
23 Oct 2012, 6:30 am
Watson Pharmaceuticals, Inc.[6] The petition seeks to overturn the Eleventh Circuit’s dismissal of the FTC’s challenge to a reverse payment settlement agreement between Solvay Pharmaceuticals, Inc., and several generic manufacturers over a drug called Androgel. [read post]
28 Oct 2007, 6:02 am
Axcan Scandipharm Inc. v. [read post]
7 Nov 2014, 5:52 am
Teva Pharmaceuticals USA, Inc., 819 F. [read post]
11 Mar 2013, 12:49 pm
Mar. 5, 2013), the plaintiffs were qui tam relators who’d sparked investigations by state AGs into alleged False Claims Act violations by the pharmaceutical manufacturer, Abbot Products, Inc., which was later acquired by Solvay Pharmaceuticals, Inc.. [read post]
17 Jun 2013, 1:21 pm
The initial patent had run out, but the U.S. licensee — Solvay Pharmaceuticals, Inc. [read post]
8 Jan 2009, 4:07 am
Solvay Pharmaceuticals, Inc., ___ F. [read post]
5 Jul 2007, 10:37 am
Solvay Pharmaceuticals, Inc., 350 F. [read post]
2 Jun 2011, 12:46 pm
Ortho Pharmaceutical Corp., 661 N.E.2d 352, 354 (Ill. 1996); Frye v. [read post]
24 Sep 2009, 5:09 am
Solvay America, Inc., 212 P.3d 614, 632 (Wyo. 2009); Lovick v. [read post]
28 Sep 2009, 1:31 am
Solvay America, Inc., 212 P.3d 614, 632 (Wyo. 2009); Lovick v. [read post]
28 Sep 2009, 1:31 am
Solvay America, Inc., 212 P.3d 614, 632 (Wyo. 2009); Lovick v. [read post]
28 Sep 2009, 1:31 am
Solvay America, Inc., 212 P.3d 614, 632 (Wyo. 2009); Lovick v. [read post]
15 Apr 2011, 6:02 am
Mylan Pharmaceuticals, Inc., 2009 WL 7115134, at *2 (N.D. [read post]
18 Feb 2010, 10:34 am
Mylan followed Sandoz Pharmaceuticals Corp. v. [read post]
29 Nov 2010, 12:23 am
Int’l., Inc. v. [read post]
28 Apr 2011, 3:18 pm
Even where a product’s risks were unavoidable, it required an independent balancing of risks and benefits – the kind of thing the FDA does – before the risks involved would be considered “apparently reasonable. [read post]
